Future molecular targets

  • Keystone Edward C. 
  • Haraoui Boulos 
Part of the Progress in Inflammation Research book series (PIR)


Over the past 20 years, biotechnology has pioneered the development of genetically engineered therapies that target specific aspects of the immune response. However, biologic agents are frequently immunogenic, requiring complex and labor intensive production processes and parenteral administration, resulting in high costs which limit both availability and access to treatment.


Collagen Induce Arthritis Rheumatoid Arthritis Synovium Mitogen Activate Protein Kinase Pathway Mitogen Activate Protein Kinase Cascade Anti Sense Oligonucleotide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Firestein GS, Manning M (1999) Signal transduction and transcription factors in rheumatic diseases. Arthritis Rheum 42: 609–621CrossRefPubMedGoogle Scholar
  2. 2.
    Piecyk M, Anderson P (2001) Signal transduction in rheumatoid arthritis. Best Practice and research. Clin Rheumatol 15: 789–803Google Scholar
  3. 3.
    Handel ML, Gurgis L (2001) Transcription factors. Best Practice and Research. Clin Rheumatol 15: 657–675Google Scholar
  4. 4.
    Angel P, Karin M (1991) The role of Jun, Fas and the AP-1 complex in cell proliferation and transformation. Biochem Biophys Acta 1072: 129–157PubMedGoogle Scholar
  5. 5.
    Kinne RW, Boehim S, Iftner T et al (1995) Synovial fibroblast-like cells strongly express jun-B and c-fas proto-oncogenes in rheumatoid and osteoarthritis. Scand J Rheumatol 101: Suppl 121–125CrossRefGoogle Scholar
  6. 6.
    Deleuran BW, Chu GQ, Field M Brennan FM, Mitchell T, Feldmann M, Maini RN (1992) Localization of tumor necrosis factor receptors in the synovial tissue and cartilage pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 35: 1170–1178CrossRefPubMedGoogle Scholar
  7. 7.
    Han Z, Boyle DL, Manning A et al (1998) AP-1 and NFKB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28: 197–208CrossRefPubMedGoogle Scholar
  8. 8.
    Schett G, Tohidast-Akrad M, Smolen JS, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G (2000) Activation, differential localization and regulation of the stress activated protein kinases, extracellular signal regulated kinase, C-Jun N-terminal kinase and p38 mitogen activated protein kinase in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43: 2501–2502CrossRefPubMedGoogle Scholar
  9. 9.
    Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin Invest 108: 73–81PubMedGoogle Scholar
  10. 10.
    Han Z, Chang L, Yamanishi Y (2002) Joint damage and inflammation in c-Jun N-terminai kinase Z knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 46: 818–823CrossRefPubMedGoogle Scholar
  11. 11.
    Herlaar E, Brown Z (1999) p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 5: 439-447Google Scholar
  12. 12.
    Shiojawa S, Shimizu K, Tanaka K et al (1997) Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J. Clin Invest 99: 1210–1216CrossRefGoogle Scholar
  13. 13.
    Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL (2000) Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacol 47: 185–201CrossRefGoogle Scholar
  14. 14.
    Adams JL, Badger AM, Kumar S, Lee JC (2001) p38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem 38: 1–60CrossRefPubMedGoogle Scholar
  15. 15.
    Handel ML, McMorrow LB, Gravellese EM (1995) Nuclear factor KB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 38: 1762–1770CrossRefPubMedGoogle Scholar
  16. 16.
    Roshak AK, Callahan JF, Blake SM et al (2002) Small molecule inhibitors of NFKB for the treatment of inflammatory joint disease. Curr Opinion in Pharmacol 2: 316–321CrossRefGoogle Scholar
  17. 17.
    Aupperle KB, Bennet BL, Boyle DL et al (1999) NFKB regulation by I kappa B kinase in primary fibroblast-like synoviocytes. J. Immunol 163: 427PubMedGoogle Scholar
  18. 18.
    Tak PP, Gerlag DM, Aupperle KG et al (2001 ) Inhibitor of nuclear factor kappa B kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 44: 1897–1907CrossRefPubMedGoogle Scholar
  19. 19.
    Miagkov AV, Kovalenko DV, Brown CE (1998) NF kappab activation provides the potential link between inflammation and hyperplasia in the arthritis joint. Proc Natl Head Sei USA 95: 13859–13864CrossRefGoogle Scholar
  20. 20.
    Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y et al (1999) Suppressed severity of collagen induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxyonucleotides as a gene therapy. Arthritis Rheum 42: 2532–1242CrossRefPubMedGoogle Scholar
  21. 21.
    Yokota A, Narazaki M, Shima Y, Murata N, Tanaka T, Suemura M, Yoshizaki K, Fujiwara H, Tsuyuguchi I, Kishimoto T (2001) Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial cells. J. Rheum 28: 1952–1959PubMedGoogle Scholar
  22. 22.
    Crooke ST (1999) Molecular mechanisms of antisense drugs: human RnaseH. Antisense Nucleic Acid Drug Dev 9: 377Google Scholar
  23. 23.
    Moss ML, White JM, Andrews RC (2001) TACE and other ADAM proteases as targets for drugs discovery. Drug Discov Today 6(8): 417–426CrossRefPubMedGoogle Scholar
  24. 24.
    Randle JC, Harding MW, Ku G et al (2001) ICE/Caspase-1 inhibitors as novel antiinflammatory drugs. Expert Opin Investig Drugs 10 (7): 1207–1209CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Keystone Edward C. 
    • 1
    • 2
    • 3
  • Haraoui Boulos 
    • 4
  1. 1.University of TorontoCanada
  2. 2.Université de MontréalMontréalCanada
  3. 3.The Rebecca MacDonald Centre for Arthritis and Autoimmune DiseaseMount Sinai HospitalTorontoCanada
  4. 4.CHUMHôpital Notre-DameMontréalCanada

Personalised recommendations